Table 1. Basic characters.
| Sacubitril/valsartan, n = 93 | |
| Follow-up days | 231.7 ± 153.9 (2016/03/28-2018/01/11) |
| Duration of CHF (mean ± SD) | 1242.1 ± 1483.6 (2003/07/07-2018/01/04) |
| Male | 67 (72%) |
| Female | 26 (28%) |
| Age (mean ± SD) | 67.1 ± 12.4 (37-93) |
| SBP (mmHg) | 127 ± 19 |
| NYHA functional class – no. (%) | |
| NYHA I-II | 62 (67%) |
| NYHA III-IV | 31 (33%) |
| Clinical feature of heart failure | |
| Dilated cardiomyopathy | 43 (46%) |
| Ischemic cardiomyopathy | 50 (54%) |
| Range of LVEF (%) | 19-39 |
| LVEF (mean ± %) | 34.4 ± 5.0 |
| Lab data | |
| NT-proBNP (pg/ml) | 6379 (38-27960) |
| Creatinine (mg/dl) | 1.5 ± 0.3 |
| Potassium (mEq/l) | 4.29 ± 0.58 |
| eGFR (ml/min/1.73 m2) | 63 ± 21.3 |
| BUN (mg/dl) | 20.6 ± 5.1 |
| Medical history – no. (%) | |
| Atrial fibrillation | 21 (23%) |
| Hypertension | 28 (30%) |
| Diabetes mellitus | 32 (34%) |
BUN, blood urea nitrogen; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; LVEF, left ventricule ejection fraction; NT-proBNP, N-terminal pro–B-type natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation.